EUVIMEDObjevte EUVIMED
BeobachtungsstudieMultizentrische StudieOpen access · CC BY 4.0

Treatment Patterns, Outcomes and Healthcare Resource Utilization of Obstructive Hypertrophic Cardiomyopathy in England

Faizel Osman, Carla L Zema, Michael Hurst, Belinda Sandler, Florence Brellier, Ovie Utuama, Oksana Kirichek, John Houghton, Teresa Lemmer, Maite Tome Esteban

ESC Heart Failure · 2025

DOI: 10.1002/ehf2.15213 ↗

At a glance

Beobachtungsstudie in ESC Heart Failure, 2025. Written by Faizel Osman and 9 co-authors. Institution: Institute of Cardio-Metabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK. Major MEDLINE topics: Cardiomyopathy, Hypertrophic, Patient Acceptance of Health Care, Health Resources. Cited 2 times so far (Crossref); 43 references. The full text is freely available (open access, CC BY 4.0). Funded by: Bristol Myers Squibb, Bristol-Myers Squibb Canada.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Aims

Describe patient characteristics, treatment patterns, clinical outcomes, healthcare resource utilization (HCRU) and medical costs associated with patients who were diagnosed with obstructive hypertrophic cardiomyopathy (HCM) in clinical practice in England. Methods and results This observational, retrospective, cohort study of adults who were diagnosed with obstructive HCM in routine clinical practice in England used electronic health records from Clinical Practice Research Datalink (CPRD) GOLD/Aurum and linked Hospital Episode Statistics (HES) databases (1 April 2007 to 30 October 2020). Adults (≥18 years at index date) with at least one diagnosis code (ICD-10, Read, SNOMED, or OPCS) indicative of HCM with ≥1 year of continuous registration in CPRD, data of acceptable research quality and eligibility for HES linkage were included. Outcomes from the obstructive HCM cohort were stratified by New York Heart Association (NYHA) class at baseline and during follow-up. Owing to the paucity of NYHA coding, patients with obstructive HCM and no record of NYHA class were assigned a proxy NYHA classification using an algorithm that considered patient symptoms and treatments. The study included 6440 patients in the overall HCM cohort with a mean follow-up duration of 4.84 [standard deviation (SD): 2.95] years. The study population was predominantly male (61.9%) and white (79.1%), with a mean (SD) age of 61.02 (15.61) years. The proportion of patients with obstructive HCM who had a pre-specified prior medical condition relevant to understanding disease burden increased with higher NYHA class (66.5% vs. 83.0% for NYHA class I and NYHA class II+, respectively), as did the proportion of patients with at least one baseline active prescription for cardiovascular-related medication. Among patients with at least one record of a prescription for the treatment of symptomatic obstructive HCM, 41.7% experienced a treatment change during the follow-up period. Atrial fibrillation or flutter, ischaemic stroke and heart failure were the most observed clinical events among patients in the obstructive HCM cohort, and the first in-study incidence of these events increased with higher NYHA class. Total HCRU costs per patient-year increased from £3033 to £4517 for NYHA classes I and II+, respectively, with secondary care costs consistently being the main driver in the obstructive HCM cohort.

Conclusions

Obstructive HCM is associated with a large clinical and economic burden in England, and this burden increases with higher NYHA class. These findings support the need for new and more effective strategies for the management of HCM.

Subjects

MeSH terms (MEDLINE)

Cardiomyopathy, HypertrophicPatient Acceptance of Health CareHealth ResourcesHumansMaleFemaleRetrospective StudiesEnglandMiddle AgedFollow-Up StudiesAgedAdultTreatment Outcome

Author keywords

Clinical outcomesHealthcare resource utilizationHypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyPatient characteristicsTreatment patterns

Authors and institutions

  • Institute of Cardio-Metabolic Medicine, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.
  • Warwick Medical School, University of Warwick, Coventry, UK.
  • Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Bristol Myers Squibb, Uxbridge, UK.
  • Health Economics and Outcomes Research Ltd, Cardiff, UK.
  • Cardiovascular Clinical Academic Group, St George's Hospital NHS Foundation Trust, London, UK.

Funding

  • Bristol Myers Squibb
  • Bristol-Myers Squibb Canada

Cite

APA

Osman, F., Zema, C. L., Hurst, M., Sandler, B., Brellier, F., Utuama, O., Kirichek, O., Houghton, J., Lemmer, T., & Esteban, M. T. (2025). Treatment Patterns, Outcomes and Healthcare Resource Utilization of Obstructive Hypertrophic Cardiomyopathy in England. ESC Heart Failure. https://doi.org/10.1002/ehf2.15213

Vancouver

Osman F, Zema CL, Hurst M, Sandler B, Brellier F, Utuama O, et al. Treatment Patterns, Outcomes and Healthcare Resource Utilization of Obstructive Hypertrophic Cardiomyopathy in England. ESC Heart Failure. 2025. doi:10.1002/ehf2.15213

BibTeX
@article{Osman2025,
  author = {Osman, Faizel and Zema, Carla L and Hurst, Michael and Sandler, Belinda and Brellier, Florence and Utuama, Ovie and Kirichek, Oksana and Houghton, John and Lemmer, Teresa and Esteban, Maite Tome},
  title = {Treatment Patterns, Outcomes and Healthcare Resource Utilization of Obstructive Hypertrophic Cardiomyopathy in England},
  journal = {ESC Heart Failure},
  year = {2025},
  doi = {10.1002/ehf2.15213}
}
Start for free →